Julian G. Hurdle, Ph.D., is a leading scientist in the infectious disease field, conducting research and mentoring trainees on antibiotic resistance, microbial pathogenesis, and drug discovery with the goal of translating his research to improve human health. He is currently a Professor of Microbiology in the Institute of Biosciences and Technology (IBT) in the Department of Translational Medical Sciences at Texas A&M Health Science Center. He received his B.S. from the University of West Indies, Cave Hill Campus in Barbados, graduating with first class honors in Biology and Chemistry. He obtained his Ph.D. in Microbiology from the University of Leeds, United Kingdom and undertook postdoctoral training and research at University of Tennessee Health Science Center and St Jude Children’s Research Hospital. Dr. Hurdle has an outstanding training record, impacting the careers of numerous undergraduates, graduates, and post-doctoral trainees. He was appointed as the Director of the Postdoctoral Training Program at the IBT, helping to provide an environment for professional growth. He serves on the steering committees of two T32 graduate and postdoctoral NIH training grants within the Texas Medical Center. He also serves the Texas scientific community through an initiative by the Gulf Coast Consortia to tackle antibiotic resistance through research and education. Dr. Hurdle regularly serves on NIH study sections and is an editorial board member of top-tier journals in infectious diseases. His translational research characterizes the genetic mechanisms of antibiotic resistance and their impact on treatment outcomes, while discovering innovative therapeutic concepts to counter antibiotic-resistant bacteria. Dr. Hurdle has been continuously extramurally funded, namely by the National Institute of Health (NIH). His research is published in leading peer-review journals and is credited with the recent breakthrough explaining how the evolution of antibiotic resistance in Clostridiodes difficile contributed to the pandemic spread of this pathogen and its association with poorer clinical outcomes in patients.